Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life after its 2028 patent cliff.

2 December 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026.

2 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025.

2 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on whether the pipeline can deliver enough growth to meet GSK’s ambitious 2031 revenue targets. Hargreaves Lansdown+2Yahoo Finance+2

2 December 2025

Earnings Reports·LSE:GSK·NYSE:GSK·Pharmaceuticals·Stock Market

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer’s share price is exploding today. On 2 December 2025, the German blue chip is trading around €34–35 on Xetra, up roughly 13% intraday and at a fresh year high.FinanzNachrichten.de+1

2 December 2025

Pharmaceuticals·Stock Market·XETRA:BAYN

Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt Limited has suddenly jumped back into the market spotlight. On 2 December 2025, the Wockhardt share price extended a powerful breakout rally triggered by a landmark US regulatory milestone for its novel antibiotic Zaynich, making the stock one of the most-watched names in India’s pharma space this week. NDTV Profit+1

2 December 2025

NSE:WOCKPHARMA·Pharmaceuticals·Stock Market

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock.The Motley Fool+1

1 December 2025

Earnings Reports·Healthcare Innovation·NYSE:ABBV·Pharmaceuticals·Stock Market

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK plc heads into December 2025 as one of the stronger-performing big pharma names, with the share price hovering just below a 52‑week high after a year of earnings beats, upgraded guidance, revived cancer assets and a looming CEO handover.

1 December 2025

NYSE:GSK·Pharmaceuticals·Stock Market

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November 28–30.

30 November 2025

NYSE:PFE·Pharmaceuticals·Stock Market

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30.

30 November 2025

NYSE:ABBV·Pharmaceuticals

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly and Company heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity drugs, and a late‑month pullback as investors digest aggressive US drug‑pricing deals and sky‑high valuations.

30 November 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are digesting in real time.

30 November 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as the stock market’s flagship obesity‑drug play. At the same time, fresh commentary this weekend is increasingly focused on one question: is Lilly’s stock now priced for perfection?

30 November 2025

NYSE:LLY·Pharmaceuticals·Stock Market

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie Inc. heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1

29 November 2025

Healthcare News·NYSE:ABBV·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly and Company’s stock has cooled after an explosive November rally that briefly turned the 149‑year‑old drugmaker into the world’s first trillion‑dollar pharmaceutical company.Reuters+1

29 November 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare giant a market capitalization of roughly $500 billion.FinancialContent

28 November 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Pfizer stock is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3% from yesterday’s close near $25.72.MarketBeat

28 November 2025

NYSE:PFE·Pharmaceuticals·Stock Market

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs.

28 November 2025

LSE:GSK.L·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin.

26 November 2025

CPH:NOVO-B·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news on obesity drugs, cancer treatment and vaccines against ongoing legal and regulatory risks. MarketScreener+1

26 November 2025

NYSE:PFE·Pharmaceuticals

Previous 1 … 40 41 42 43 44 … 49 Next

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

TechStock² Updates

Medtronic Shares Climb 3.2% Following Upgraded Outlook and $700 Million Investment in Robotics

Ambev ADR Rises 0.7% as Brazilian Beer Sales Support Margin Outlook

Nasdaq Futures Drop 1.35% as Crude Surpasses $92 and Bond Yields Climb

GoPro Surges 64% Premarket After $87 Million Debt Faces Markiplier-Led Rally

American Airlines Shares Dip 1.2% With $92 Oil Squeezing Earnings Margins

Nasdaq Futures Fall 1.2% as 10-Year Treasury Yield Approaches 4.8%

Netflix’s The Secret Woman Hits No. 2 as $25 Billion Content Commitments Face a Returns Test

Energy Soars 3.3% With Oil Approaching $92; QQQ Declines

NIO Stock Drops 1.2% as Revenue Guide Slows to 4.8% Growth

SCHD up 24%, yield trails Treasuries by 1.6 points

Investment Disclaimer